Tumoral MGMT content predicts survival in patients with aggressive pituitary tumors and pituitary carcinomas given treatment with temozolomide

Endocrine. 2018 Dec;62(3):737-739. doi: 10.1007/s12020-018-1751-9. Epub 2018 Sep 24.

¹ Department of Endocrinology, Kalmar, Kalmar County Council and Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden.
² Department of Pathology, Odense University Hospital, University of Southern Denmark, Odense, Denmark.
³ Department of Molecular Medicine and Surgery, Patient Area Endocrinology and Nephrology, Inflammation and Infection Theme, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden.
⁴ Department of Endocrinology and Nutrition, Cliniques Universitaires St-Luc, Université Catholique de Louvain, Brussels, Belgium.
⁵ Department of Internal Medicine and Clinical Nutrition, Sahlgrenska Academy, University of Gothenburg and Department of Endocrinology, Sahlgrenska University Hospital, Gothenburg, Sweden.
⁶ Department of Medical Endocrinology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
⁷ Department of Medicine, Division of Endocrinology, Erasmus University, Rotterdam, The Netherlands.
⁸ Department of Endocrinology, Odense University Hospital, University of Southern Denmark, Odense, Denmark.
⁹ Department of Endocrinology, Skåne University Hospital, University of Lund, Malmo, Sweden. [email protected].

No abstract available

Publication types